Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting the population for gene therapy with MYBPC3.

Journal of molecular and cellular cardiology - 1 Jan 2021

Carrier Lucie

Abstract excerpt

Hypertrophic cardiomyopathy (HCM) is the most prevalent inherited myocardial disease characterized by unexplained left ventricular hypertrophy, diastolic dysfunction and myocardial disarray. Clinical heterogeneity is wide, ranging from asymptomatic individuals to heart failure, arrhythmias and sudden death. HCM is often caused by mutations in genes encoding components of the sarcomere. Among them, MYBPC3,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Age Factors
Share to Cardiomyopathy and Myosin Studies
Share to Cardiomyopathy, Hypertrophic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carrier Proteins

Share to Genetic Therapy

Share to Heart Transplantation

Share to Mutation

Share to Viral Infections and Immunology Research

Source

Identifiers

PMID: 33049255
DOI: 10.1016/j.yjmcc.2020.10.003

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting the population for gene therapy with MYBPC3.PMID 33049255Read ↗

Cardiac myosin-binding protein C (MYBPC3) in cardiac pathophysiology.Semantic proximity Read ↗

An Update on MYBPC3 Gene Mutation in Hypertrophic Cardiomyopathy.Semantic proximity Read ↗

Screening Mutations of MYBPC3 in 114 Unrelated Patients with Hypertrophic Cardiomyopathy by Targeted Capture and Next-generation Sequencing.Semantic proximity Read ↗

Protein haploinsufficiency drivers identify<i>MYBPC3</i>mutations that cause hypertrophic cardiomyopathySemantic proximity Read ↗

Hypertrophic cardiomyopathy in MYBPC3 carriers in agingSemantic proximity Read ↗

Evolution of genetic testing and gene therapy in hypertrophic cardiomyopathy.Semantic proximity Read ↗

Mavacamten shows broad benefit in human and mouse models of MYBPC3-related hypertrophic cardiomyopathy.Semantic proximity Read ↗

Whole MYBPC3 NGS sequencing as a molecular strategy to improve the efficiency of molecular diagnosis of patients with hypertrophic cardiomyopathy.Semantic proximity Read ↗

MYBPC3 in hypertrophic cardiomyopathy: from mutation identification to RNA-based correctionSemantic proximity Read ↗

Protein haploinsufficiency drivers identify MYBPC3 variants that cause hypertrophic cardiomyopathy.Semantic proximity Read ↗

A Novel Truncating Variant in MYBPC3 Causes Hypertrophic CardiomyopathySemantic proximity Read ↗

Spectrum and clinical manifestations of mutations in genes responsible for hypertrophic cardiomyopathy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.